Status:

COMPLETED

Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial

Lead Sponsor:

Central Institute of Mental Health, Mannheim

Conditions:

Schizophrenia, Schizoaffective Disorder

Eligibility:

All Genders

18-70 years

Phase:

PHASE4

Brief Summary

We aim to compare the augmentation of clozapine with ziprasidone or risperidone in a randomized, prospective manner.

Detailed Description

Partial response of schizophrenic psychoses to a monotherapy with clozapine is a frequent problem of clinical psychiatry. Current problems are treatment resistant positive and/or negative symptoms, as...

Eligibility Criteria

Inclusion

  • Treatment resistant schizophrenic or schizoaffective disorder under therapy with clozapine,
  • Age between 18 and 70,
  • Informed consent

Exclusion

  • No informed consent,
  • Intolerance with respect to ziprasidone or risperidone,
  • Contraindications with respect to these substances,
  • Gravidity or missing anticonceptive safety
  • Substance dependance (excluded nicotin)

Key Trial Info

Start Date :

November 1 2003

Trial Type :

INTERVENTIONAL

End Date :

September 1 2006

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT00224315

Start Date

November 1 2003

End Date

September 1 2006

Last Update

June 4 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Central Institute of Mental Health, Department of Psychiatry,

Mannheim, Baden-Wurttemberg, Germany, 68159